<DOC>
	<DOCNO>NCT02356809</DOCNO>
	<brief_summary>The purpose study determine whether pl-vegf165 ( Neovasculgen ) effective treatment digital ulcer related secondary Raynaud 's phenomenon associate systemic scleroderma</brief_summary>
	<brief_title>Safety Efficacy Study Gene Therapy Drug ( Neovasculgen ) Treat Secondary Raynaud 's Phenomenon</brief_title>
	<detailed_description>This randomize , open , compare clinical trial assess therapeutic efficacy pl-vegf165 ( Neovasculgen ) treat scleroderma-associated Raynaud 's syndrome . Each patient clinical group undergo several intramuscular injection treatment dose pl-vegf165 ( Neovasculgen ) hand digital ulcer locate . In control group patient receive standard care without gene therapy drug . Study participant first study visit complete study questionnaire , hand assess clinically digital ulceration , hand undergo non-invasive capillaroscopy . After initial assessment , patient clinical group undergo intramuscular injection pl-vegf165 ( Neovasculgen ) hand alter digital ulcer . Patient report severity Raynaud 's symptom weekly six month study period . At three month post-injection , patient complete study questionnaire , hand assess clinically digital ulceration , hand undergo non-invasive capillaroscopy . At six month post-injection , patient complete study questionnaire , hand assess clinically digital ulceration , hand undergo non-invasive capillaroscopy .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<criteria>obtain voluntary informed consent participation clinical study presence systemic scleroderma feature satisfy criterion American College Rheumatology classification presence least one active digital ulcer baseline presence another systemic connective tissue disease ; absence least one active digital ulcer baseline ; smoke within 3 month smoke cessation use nicotine product ; subject currently take sildenafil , tadalafil vardenafil ; history sympathectomy previous 12 month able unwilling give voluntary inform consent study follow requirement clinical study ; decompensated chronic visceral disease ; clinically significant laboratory abnormality ; HIV , HBV HCV antibodies serum ; alcohol drug addiction ; participation clinical study ( administration study product ) within 3 month prior study ; condition limit study compliance ( dementia , psychoneurological disease , drug addiction , alcoholism , etc . ) ; malignancy include postsurgical period chemo ( ) radiation therapy ) ; vascular malformation ; pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Gene therapy , plasmid , vegf , systemic scleroderma , secondary raynaud 's phenomenon</keyword>
</DOC>